YS vs. PRPH, ETON, ONCY, VACC, QTTB, ACRS, MIST, CMRX, LFVN, and BYSI
Should you be buying YS Biopharma stock or one of its competitors? The main competitors of YS Biopharma include ProPhase Labs (PRPH), Eton Pharmaceuticals (ETON), Oncolytics Biotech (ONCY), Vaccitech (VACC), Q32 Bio (QTTB), Aclaris Therapeutics (ACRS), Milestone Pharmaceuticals (MIST), Chimerix (CMRX), LifeVantage (LFVN), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical preparations" industry.
ProPhase Labs (NASDAQ:PRPH) and YS Biopharma (NASDAQ:YS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
ProPhase Labs presently has a consensus price target of $11.00, indicating a potential upside of 117.82%. YS Biopharma has a consensus price target of $5.25, indicating a potential upside of 441.24%. Given ProPhase Labs' higher probable upside, analysts clearly believe YS Biopharma is more favorable than ProPhase Labs.
ProPhase Labs has higher earnings, but lower revenue than YS Biopharma.
ProPhase Labs has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, YS Biopharma has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
YS Biopharma has a net margin of 0.00% compared to YS Biopharma's net margin of -82.18%. ProPhase Labs' return on equity of 0.00% beat YS Biopharma's return on equity.
ProPhase Labs received 113 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 50.44% of users gave ProPhase Labs an outperform vote.
In the previous week, ProPhase Labs had 2 more articles in the media than YS Biopharma. MarketBeat recorded 7 mentions for ProPhase Labs and 5 mentions for YS Biopharma. ProPhase Labs' average media sentiment score of 1.24 beat YS Biopharma's score of 0.18 indicating that YS Biopharma is being referred to more favorably in the news media.
9.5% of ProPhase Labs shares are owned by institutional investors. Comparatively, 52.6% of YS Biopharma shares are owned by institutional investors. 26.1% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
YS Biopharma beats ProPhase Labs on 9 of the 14 factors compared between the two stocks.
Get YS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
YS Biopharma Competitors List
Related Companies and Tools
